The long-term goal of our research is to study the role of multiple cellular pathways in cancer cells and their microenvironment during progression to metastasis and treatment resistance. We also aim at developing small molecule inhibitors for targeted therapy and personalized medicine for treatment of metastatic prostate cancer, breast cancer, and colon, lung and pancreatic cancers that share common K-RAS mutations.
Our research expertise spans in molecular genetics, stem cell biology, immunology, signaling transduction and cancer biology. We developed novel drug candidates to target cancer-initiating cells. We play a leading role in cancer research at international forefront. We have established extensive networks and interdisciplinary research collaborations with national and international clinical and preclinical experts and industries. We have two large EU framework project grants EU –GlycoImaging 721297, EU-REVERT no848098-H2020-SC1-2, and the Swedish National Research Council, the Swedish Cancer Foundation and the Swedish Children Cancer Foundation. I am a board member of Research Grant Review committee in the Swedish Cancer Foundation. I serve as board member of University Council for Artificial Intelligence at Umeå University.
Most of our publications can be found in journals: Proc Natl Acad Sci U S A, Cancer Research, Blood, Oncogene, Journal of National Cancer Institute, Leukemia, International Journal of Cancer, Journal of Molecular Biology, Oncotarget, PLos One, International Journal of Cancer, Current Targeted Cancer Therapy, and Current Medicinal Chemistry.